Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of up to $370 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates.

We also have number of additional partnerships under negotiation. These partnership agreements represent the start of CEPI’s product development portfolio. See below current details of our vaccine portfolio.

PRODUCT DEVELOPERS
  • All
  • IDT Biologika
  • Imperial College London
  • Inovio Pharmaceuticals
  • International AIDS Vaccine Initiative
  • Janssen Vaccines & University of Oxford
  • Profectus Biosciences, Emergent Biosolutions & PATH
  • Themis Bioscience
  • University of Queensland
DISEASE
  • All
  • Inflluenza virus
  • Lassa virus
  • Marburg virus
  • MERS coronavirus
  • Nipah virus
  • Rabies virus
  • Respiratory syncytial virus
VACCINE TYPE
  • All
  • ASPIRE (DNA vaccine)
  • Measles vector
  • Molecular clamp platform
  • Recombinant Modified Vaccinia Ankara
  • Replication-deficient simian adenoviral vaccine vector, ChAdOx1
  • rVSVNC4ΔG
  • rVSVΔG
  • saRNA platform
  • VesiculoVax
PHASE
  • All
  • Phase 1
  • Phase 2
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:
{{ dev['developer'] }}
{{ d['disease'] }}
{{ d['vaccine_type'] }}
Clinical Trial Registry No.
{{ d['trial'] }}
CEPI Funding (USD)
{{ d['usd'] }}
N/A
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result